isradipine vs hydrochlorothiazide | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 1.54 [0.71 3.33] | p=1.00 | 0 | 883 | 1 | MIDAS, | Cardiovascular death | no data | stroke (fatal and non fatal) | 2.00 [0.50 8.03] | p=1.00 | 0 | 883 | 1 | MIDAS, | Coronary event | 1.20 [0.36 3.95] | p=1.00 | 0 | 883 | 1 | MIDAS, | Fatal MI | no data | Non fatal MI | 1.20 [0.36 3.95] | p=1.00 | 0 | 883 | 1 | MIDAS, | Heart failure | 4.99 [0.24 104.22] | p=1.00 | 0 | 883 | 1 | MIDAS, | Diabetes onset | no data | Angina | no data | Peripheral arterial disease | no data | End stage renal disease | no data | Revascularization | no data | All cause death | 0.89 [0.34 2.32] | p=1.00 | 0 | 883 | 1 | MIDAS, | Fatal stroke | no data | Non fatal stroke | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |